AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) extended the subscription period for its previously announced rights offering to 5:00 p.m. ET on March 3, 2026. The offering commenced on February 11, 2026 and subscription rights are non-transferable and exercisable only during the subscription period.
The company stated the SEC declared its Form S-1 effective on February 10, 2026. Maxim Group LLC is engaged as dealer-manager and Broadridge will act as subscription agent for receipt of completed rights certificates and payment.
Positive
- Subscription period extended to March 3, 2026
- SEC declared Form S-1 effective on February 10, 2026
- Maxim Group engaged as dealer-manager
Negative
- Subscription rights are non-transferable and expire if unexercised
- Exercise of rights is irrevocable even if adverse information emerges
- Company may cancel or modify the rights offering prior to expiration
Key Figures
Market Reality Check
Peers on Argus
AIM fell 0.93% while close biotech peers showed mixed moves (e.g., TNFA -9.72%, BCLI +3.91%, HCWB -6.72%), indicating a largely stock-specific reaction rather than a coordinated sector move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Rights offering terms | Negative | -6.4% | Correction detailing rights offering size, unit structure and timelines. |
| Feb 11 | Rights offering launch | Negative | -13.5% | Commencement of rights offering with preferred shares and warrants package. |
| Jan 27 | Offering terms change | Negative | +0.0% | Amendment to key dates and terms for the planned rights offering. |
| Jan 23 | Proposed rights deal | Negative | -5.2% | Announcement of proposed rights offering targeting up to $12M in proceeds. |
| Jul 31 | Public equity offering | Negative | -4.3% | Closing of $8M public offering of shares and warrants under S-1. |
Offering-related announcements have typically pressured AIM’s stock, with an average same-tag move of -5.86% and 4 of 5 events showing declines on financing news.
Over recent months, AIM has repeatedly used equity financing, including rights-offering announcements and amendments targeting up to $12.0 million in proceeds via Series G preferred and warrant-heavy Units. These steps follow earlier public offerings and occur alongside continued clinical work on Ampligen for metastatic pancreatic cancer. Today’s extension of the rights-offering subscription period continues this capital-raising sequence framed in prior S-1 and 424B4 filings and maintains focus on funding pancreatic cancer programs and debt reduction.
Historical Comparison
In the past year AIM’s offering headlines averaged a -5.86% move. This extension of the ongoing rights offering fits the same dilution-focused financing pattern.
The rights offering progressed from initial terms in Jan 2026, through amended dates and formal commencement in Feb 2026, to a corrected prospectus summary and now an extended subscription deadline, all tied to the same $12M capital-raise structure.
Regulatory & Risk Context
AIM has an effective S-3/A shelf filed on 2025-06-27 authorizing issuance of up to $100 million in securities, including common and preferred stock, debt and warrants. Recent 424B4 and 424B5 usages show the shelf being tapped for structured offerings, implying ongoing flexibility but also continued dilution potential as additional tranches are executed.
Market Pulse Summary
This announcement extends the subscription window for AIM’s ongoing rights offering to 5:00 p.m. ET on March 3, 2026, giving eligible holders more time to decide on participation. It follows a series of filings detailing a $12.0 million preferred-and-warrant structure and sits alongside an active $100 million S-3/A shelf. Investors may focus on how much of the offering is ultimately taken down and how proceeds support pancreatic cancer programs and balance-sheet repair.
Key Terms
rights offering financial
subscription rights financial
over-subscription privilege financial
registration statement on Form S-1 regulatory
AI-generated analysis. Not financial advice.
OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026.
The subscription period for the rights offering commenced on February 11, 2026. All holders of subscription rights that wish to subscribe to the rights offering must deliver a properly completed and signed subscription rights certificate, together with payment of the full subscription price for the units the holder wishes to purchase pursuant to both the basic subscription right and the over-subscription privilege, to Broadridge Corporate Issuer Solutions, LLC (the “Subscription Agent”), to be received before 5:00 p.m., Eastern Time, on March 3, 2026. The completed rights certificate and payment should be delivered to the Subscription Agent as follows:
| By UPS, FedEx or Courier: | By USPS Service: |
| Broadridge, Inc. Attn: BCIS IWS 51 Mercedes Way Edgewood, NY 11717 | Broadridge, Inc. Attn: BCIS Re-Organization Department P.O. Box 1342 Brentwood, NY 11717-0718 |
The subscription rights are non-transferable and will only be exercisable during the subscription period. Once holders have exercised their subscription rights, such exercise may not be revoked, canceled, or changed, even if holders subsequently learn information about the Company or its business, financial position, results of operations or cash flows that is material or adverse or that the holders otherwise consider to be unfavorable. The Company may cancel, modify or amend the rights offering at any time and for any reason prior to the expiration of the subscription period. Subscription rights which are not exercised by the expiration date of the rights offering will expire and will have no value.
AIM has engaged Maxim Group LLC as dealer-manager for the proposed rights offering. Questions about the rights offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026. The prospectus relating to and describing the terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offering and an offering can only be made by the prospectus and any prospectus supplements for the rights offering, which should be read carefully before making an investment decision.
The Company's stockholders as of 5:00 p.m., Eastern Time, on February 10, 2026 – the record date – should make an independent investment decision about whether to exercise their subscription rights based on their own assessment of the Company's business, financial condition, prospects for the future and the terms of the rights offering.
About AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
Forward Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.
IR Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
When does AIM (AIM) rights offering subscription period now end?
Are AIM subscription rights transferable for the March 2026 rights offering?
How do AIM shareholders exercise their rights in the March 2026 offering?
Can AIM shareholders revoke their exercise after submitting subscription rights?
Who should AIM shareholders contact with questions about the rights offering?
